Der Gynäkologe

, Volume 40, Issue 8, pp 621–628

Hormonapplikation und gynäkologische Tumortherapie

Einfluss auf den Knochenstoffwechsel


In der Gynäkologie spielt die Osteoporose eine wesentliche Rolle. Durch gynäkologische und onkologische Therapien kann das Risiko einer Osteoporose verstärkt werden, die durch ein erhöhtes Frakturrisiko Morbidität und Mortalität erhöht, die Lebensqualität drastisch senkt und einen massiven Kostenanstieg im Gesundheitswesen bedingen kann. Klassische Medikamente der Gynäkologie, wie GnRH-Analoga und die Hormontherapeutika, zeigen einen Einfluss auf die Knochengesundheit. In der gynäkologischen Onkologie verbessern moderne Therapien das Überleben. Durch erhöhte Heilungsraten werden Patientinnen vermehrt mit den Langzeitkonsequenzen konfrontiert, wie z. B. der Verlust der Knochenmasse durch vorzeitige Ovarialinsuffizienz, GnRH-Analoga, therapeutische Ovarektomie, Aromatasehemmer und Antiöstrogene. Nebenwirkungen der gynäkologischen und onkologischen Therapien sollten bekannt, abwägbar und beherrschbar sein. Die Prävention eines Knochenverlusts muss eine hohe Priorität haben.


Knochendichte Ovarialinsuffizienz Osteoporose GnRH-Analoga Aromatasehemmer 

Hormone administration and gynecological tumor therapy

Influence on bone metabolism


Osteoporosis has a fundamental role in gynecology. Gynecological and oncological treatments can increase the risk of osteoporosis; this in turn can raise morbidity and mortality rates through an increased risk of fractures, drastically reducing the patient’s quality of life and leading to a massive increase in costs to the healthcare system. The drugs classically used in gynecology – such as gonadotropin-releasing hormone (GnRH) analogues and hormonal agents – have effects on bone health. Modern forms of treatment used in gynecological oncology are improving survival rates. As a result of increased cure rates, patients are increasingly having to come to terms with such long-term effects as loss of bone mass caused by premature ovarian insufficiency, GnRH analogues, therapeutic ovariectomy, aromatase inhibitors, and antiestrogens. The side effects of gynecological and oncological treatments should be known, capable of being assessed, and manageable. High priority needs to be given to the prevention of bone loss.


Bone density Ovarian insufficiency Osteoporosis GnRH analogues Aromatase inhibitors 


  1. 1.
    Aapro M (2006) Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: The Z-ZO-E-ZO-FAST program. Breast (Suppl 1) 15: S30–S40Google Scholar
  2. 2.
    Agarwal SK (2002) Impact of six months of GnRH agonist therapy for endometriosis. Is there an age-related effect on bone mineral density? J Reprod Med 47: 530–534PubMedGoogle Scholar
  3. 3.
    Barad D, Kooperberg C, Wactawski-Wende J et al. (2005) Prior oral contraception and postmenopausal fracture: a Women’s Health Initiative observational cohort study. Fertil Steril 84: 374–383PubMedCrossRefGoogle Scholar
  4. 4.
    Beckmann M, Braendle W, Brucker C et al. (2004) Konsensusempfehlungen zur Hormontherapie im Klimakterium und in der Postmenopause. Frauenarzt 45: 620–624Google Scholar
  5. 5.
    Beckmann MW, Braendle W, Brucker C et al. (2003) Konsensus-Empfehlungen der DGGG zur Hormontherapie (HAT) im Klimakterium und in der Postmenopause. Frauenarzt 44: 138–141Google Scholar
  6. 6.
    Bedaiwy MA, Casper RF (2006) Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril 86: 220–222PubMedCrossRefGoogle Scholar
  7. 7.
    Binder H, Dittrich R, Müller A et al. (2006) Fertilitätserhaltung bei onkologischen Therapien. Geburtsh Frauenheilkd 9: R200–R220Google Scholar
  8. 8.
    Brufsky A, Harker WG, Beck JT et al. (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25: 829–836PubMedCrossRefGoogle Scholar
  9. 9.
    Bruning PF, Pit MJ, Long-Bakker M de et al. (1990) Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61: 308–310PubMedGoogle Scholar
  10. 10.
    Cauley JA, Robbins J, Chen Z et al. (2003) Women’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290: 1729–1738 PubMedCrossRefGoogle Scholar
  11. 11.
    Coombes RC, Hall E, Gibson LJ et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081–1092PubMedCrossRefGoogle Scholar
  12. 12.
    Cooper C, Hannaford P, Croft P, Kay CR (1993) Oral contraceptive pill use and fractures in women: a prospective study. Bone 14: 41–45PubMedCrossRefGoogle Scholar
  13. 13.
    Cummings SR, Browner WS, Bauer D et al. (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of osteoporotic fractures research group. N Engl J Med 339: 733–738PubMedCrossRefGoogle Scholar
  14. 14.
    Doren M, Nilsson JA, Johnell O (2003) Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum Reprod 18: 1737–1746 PubMedCrossRefGoogle Scholar
  15. 15.
    Dowsett M, Jones A, Johnston SR et al. (1995) In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1: 1511–1515PubMedGoogle Scholar
  16. 16.
    Fisher B, Costantino JP, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388PubMedCrossRefGoogle Scholar
  17. 17.
    Fogelman I, Blake GM, Blamey R et al. (2003) Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 14: 1001–1006PubMedCrossRefGoogle Scholar
  18. 18.
    Garrett TJ, Vahdat LT, Kinne DW (1997) Systematic adjuvant therapy of breast cancer. J Surg Oncol 64: 167–172PubMedCrossRefGoogle Scholar
  19. 19.
    Glackin CA, Murray EJ, Murray SS (1992) Doxorubicin inhibits differentiation and enhances expression of the helix-loop-helix genes Id and mTwi in mouse osteoblastic cells. Biochem Int 28: 67–75PubMedGoogle Scholar
  20. 20.
    Gnant M (2004) Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrazole versus goserelin plus tamoxifen – bone density subprotocol results of a randomized multicenter trial (ABCSG-12). San Antonio Breast Cancer Symposium: Abstract 5Google Scholar
  21. 21.
    Goss PE, Strasser-Weippl K (2004) Prevention strategies with aromatase inhibitors. Clin Cancer Res 10: 372S–379SPubMedCrossRefGoogle Scholar
  22. 22.
    Gradishar WJ, Schilsky RL (1988) Effects of cancer treatment on the reproductive system. Crit Rev Oncol Hematol 82: 153–171CrossRefGoogle Scholar
  23. 23.
    Hadji P (2006) Möglichkeiten und Grenzen der HRT in der Osteoporoseprävention. Frauenarzt 47: 338–343Google Scholar
  24. 24.
    Hillner BE, Ingle JN, Chlebowski RT et al. (2004) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042–4057CrossRefGoogle Scholar
  25. 25.
    Hirbe A, Morgan EA, Uluckan O, Weilbaecher K (2006) Skeletal complications of breast cancer therapies. Clin Cancer Res 15: 6309s–6314sCrossRefGoogle Scholar
  26. 26.
    Howell A, Cuzick J, Baum M et al. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years‘ adjuvant treatment for breast cancer. Lancet 365: 60–62PubMedCrossRefGoogle Scholar
  27. 27.
    Hulley SB, Grady D (2004) The WHI estrogen-alone trial – do things look any better? JAMA 291: 1769–1771PubMedCrossRefGoogle Scholar
  28. 28.
    Jackson RD, Wactawski-Wende J, LaCroix AZ et al. (2006) Women’s Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women’s health initiative randomized trial. J Bone Miner Res 21: 817–828PubMedCrossRefGoogle Scholar
  29. 29.
    Kanis JA, Melton LJ III, Christiansen C et al. (1994) The diagnosis of osteoporosis. J Bone Miner Res 9: 1137–1141PubMedCrossRefGoogle Scholar
  30. 30.
    Kuohung W, Borgatta L, Stubblefield P (2000) Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 61: 77–82PubMedCrossRefGoogle Scholar
  31. 31.
    Lux MP, Bani MR, Fasching PA, Beckmann MW (2005) Die prophylaktische Chirurgie des Mamma- und Ovarialkarzinoms. Chirurg 76: 1145–1154PubMedCrossRefGoogle Scholar
  32. 32.
    Ma CX, Adjei AA, Salavaggione OE et al. (2005) Human aromatase: gene resequencing and functional genomics. Cancer Res 65: 11071–11082PubMedCrossRefGoogle Scholar
  33. 33.
    Mackey JR, Joy A (2005) Skeletal health in postmenopausal survivors of early breast cancer. Int J Cancer 114: 1010–1015PubMedCrossRefGoogle Scholar
  34. 34.
    Martins SL, Curtis KM, Glasier AF (2006) Combined hormonal contraception and bone health: a systematic review. Contraception 73: 445–469PubMedCrossRefGoogle Scholar
  35. 35.
    Olive DL (2005) The role of add-back therapy in the United States. Drugs Today (Barc) (Suppl A) 41: 23–26Google Scholar
  36. 36.
    Oppelt PG, Beckmann MW (2001) Risikofaktoren und -beurteilung in der Menopause. Geburtsh Frauenheilkd 61: 257–267CrossRefGoogle Scholar
  37. 37.
    Palomba S, Orio F Jr, Morelli M et al. (2002) Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. J Clin Endocrinol Metab 87: 4476–4481PubMedCrossRefGoogle Scholar
  38. 38.
    Pfeilschifter J, Diel IJ (2000) Osteoporosis due to cancer treatment: Pathogenesis and management. J Clin Oncol 18: 1570–1593PubMedGoogle Scholar
  39. 39.
    Reichmann BS, Green KB (1994) Breast cancer in young women: Effect of chemotherapy on ovarian function, fertility, and birth defects. J Natl Cancer Inst Monogr 16: 125–129Google Scholar
  40. 40.
    Rossouw JE, Anderson GL, Prentice RL et al. (2002) Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288: 321–333PubMedCrossRefGoogle Scholar
  41. 41.
    The North American Menopause Society (2007) Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 31: Epub ahead of printGoogle Scholar
  42. 42.
    Torgerson DJ, Bell-Syer SE (2001) Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285: 2891–2897PubMedCrossRefGoogle Scholar
  43. 43.
    Vehmanen L, Saarto T, Elomaa I et al. (2001) Long.-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effects of adjuvant clodronate treatment. Eur J Cancer 37: 2373–2378PubMedCrossRefGoogle Scholar
  44. 44.
    Vessey M, Mant J, Painter R (1998) Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception 57: 231–235PubMedCrossRefGoogle Scholar
  45. 45.
    Vestergaard P, Rejnmark L, Mosekilde L (2006) Oral contraceptive use and risk of fractures. Contraception 73: 571–576PubMedCrossRefGoogle Scholar
  46. 46.
    Have M von, Oppelt PG, Müller A et al. (2005) Kontrazeption. Geburtsh Frauenheilkd 9: R174–R199Google Scholar
  47. 47.
    Wheeler DL, Vander Griend RA, Wronski TJ et al. (1995) The short- and long-term effects of methotrexate on the rat skeleton. Bone 16: 215–221PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  • M.P. Lux
    • 1
  • M. Schrauder
    • 1
  • M.W. Beckmann
    • 1
  • A. Müller
    • 1
  1. 1.FrauenklinikUniversitätsklinikum ErlangenErlangenDeutschland

Personalised recommendations